Intas Pharma: Intas launches biosimilar Bevacizumab with aggressive pricing | ET HealthWorld

For Roche Avastin is one of its blockbuster drug raking in sales worth $7 billion annually, the drug maker has been making several attempts to stall biosimilar drug launches of its cancer drugs in a bid to ward off competition.

Intas spokesperson said that the company has followed all due process in getting the approval for the drug. It said that the company through its pricing strategy will expand the market which currently serves only 5% of the patients.

Read complete article here:

Intas Pharma: Intas launches biosimilar Bevacizumab with aggressive pricing, Health News, ET HealthWorld.